×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AXSM – axsome therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AXSM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/4
10:24 am
axsm
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]
Low
Report
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]
4/4
07:00 am
axsm
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
Medium
Report
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
4/3
08:03 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
Medium
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
4/2
05:02 pm
axsm
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More [Yahoo! Finance]
Low
Report
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More [Yahoo! Finance]
4/1
01:32 pm
axsm
Why Shares of Axsome Therapeutics Slumped Today [Yahoo! Finance]
Low
Report
Why Shares of Axsome Therapeutics Slumped Today [Yahoo! Finance]
4/1
09:04 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $153.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $153.00 price target on the stock.
4/1
07:12 am
axsm
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) [Yahoo! Finance]
Low
Report
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) [Yahoo! Finance]
4/1
07:00 am
axsm
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)
Low
Report
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)
Date
Time
Symbol
Company Name
Action
%Chg
2/18/2025
07:00 am
axsm
axsome therapeutics, inc.
MISS
Report
-7.4%
axsome therapeutics, inc.
2/18/2025
07:00 am
axsm
axsome therapeutics, inc.
MISS
Report
-3.9%
axsome therapeutics, inc.
2/18/2025
07:00 am
axsm
axsome therapeutics, inc.
MISS
Report
-3.7%
axsome therapeutics, inc.
2/18/2025
07:00 am
axsm
axsome therapeutics, inc.
MISS
Report
-3.3%
axsome therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/1
07:07 am
axsm
Form 8-K Axsome Therapeutics, For: Apr 01
Low
Report
Form 8-K Axsome Therapeutics, For: Apr 01
3/25
07:07 am
axsm
Form 8-K Axsome Therapeutics, For: Mar 25
Medium
Report
Form 8-K Axsome Therapeutics, For: Mar 25
3/5
07:05 am
axsm
Form 8-K Axsome Therapeutics, For: Mar 05
Low
Report
Form 8-K Axsome Therapeutics, For: Mar 05
3/3
07:06 am
axsm
Form 8-K Axsome Therapeutics, For: Mar 03
Low
Report
Form 8-K Axsome Therapeutics, For: Mar 03
2/25
08:02 pm
axsm
Form 4 Axsome Therapeutics, For: Feb 21 Filed by: Mahony Susan
Low
Report
Form 4 Axsome Therapeutics, For: Feb 21 Filed by: Mahony Susan
2/25
08:01 pm
axsm
Form 4 Axsome Therapeutics, For: Feb 21 Filed by: JEFFS ROGER
Low
Report
Form 4 Axsome Therapeutics, For: Feb 21 Filed by: JEFFS ROGER
2/25
07:59 pm
axsm
Form 4 Axsome Therapeutics, For: Feb 21 Filed by: Saad Mark E
Low
Report
Form 4 Axsome Therapeutics, For: Feb 21 Filed by: Saad Mark E
2/25
07:58 pm
axsm
Form 4 Axsome Therapeutics, For: Feb 21 Filed by: Maizel Ari
Low
Report
Form 4 Axsome Therapeutics, For: Feb 21 Filed by: Maizel Ari
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/16
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder
68.0%
4/27 Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimer’s Disease Agitation 25.0%
3/19 Form 4 Axsome Therapeutics, For: Mar 17 Filed by: TABUTEAU HERRIOT 17.1%
6/27 Form 4 Axsome Therapeutics, For: Jun 25 Filed by: Coleman Mark 13.2%
12/3 Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy 11.2%
11/8 Axsome Therapeutics, Inc (AXSM) CEO Herriot Tabuteau on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.7%
10/21 Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy 10.0%
6/12 Axsome Therapeutics Inc (NASDAQ: AXSM) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 9.2%
4/14 Axsome Therapeutics Inc (NASDAQ: AXSM) is now covered by analysts at Cowen Inc. They set an "outperform" rating on the stock. 9.1%
12/18 Axsome Therapeutics Announces Proposed Public Offering of Common Stock 8.4%
4/27 Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimer’s Disease Agitation 25.0%
3/19 Form 4 Axsome Therapeutics, For: Mar 17 Filed by: TABUTEAU HERRIOT 17.1%
6/27 Form 4 Axsome Therapeutics, For: Jun 25 Filed by: Coleman Mark 13.2%
12/3 Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy 11.2%
11/8 Axsome Therapeutics, Inc (AXSM) CEO Herriot Tabuteau on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.7%
10/21 Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy 10.0%
6/12 Axsome Therapeutics Inc (NASDAQ: AXSM) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 9.2%
4/14 Axsome Therapeutics Inc (NASDAQ: AXSM) is now covered by analysts at Cowen Inc. They set an "outperform" rating on the stock. 9.1%
12/18 Axsome Therapeutics Announces Proposed Public Offering of Common Stock 8.4%
TOP News Decliners
3/13
Axsome Therapeutics Inc (NASDAQ: AXSM) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
-29.5%
8/14 Axsome Therapeutics Inc (NASDAQ: AXSM) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -14.1%
4/27 Form 8-K Axsome Therapeutics, For: Apr 27 -12.8%
3/12 Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update -11.9%
3/30 Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications -11.4%
4/6 Axsome Therapeutics Inc (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock. -10.8%
11/7 Q3/2019 9/30/2019 EPS -0.560 ZacksConsensus -0.410 ActVsEst (0.150) - Miss -10.5%
12/4 Axsome Therapeutics Inc (NASDAQ: AXSM) had its price target raised by analysts at Guggenheim from $65.00 to $48.00. -8.8%
12/1 3 Top Biotech Stocks to Buy in December [The Motley Fool] -8.6%
3/24 Here's Why The Best Is Yet to Come for Axsome Therapeutics [The Motley Fool] -7.3%
8/14 Axsome Therapeutics Inc (NASDAQ: AXSM) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -14.1%
4/27 Form 8-K Axsome Therapeutics, For: Apr 27 -12.8%
3/12 Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update -11.9%
3/30 Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications -11.4%
4/6 Axsome Therapeutics Inc (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock. -10.8%
11/7 Q3/2019 9/30/2019 EPS -0.560 ZacksConsensus -0.410 ActVsEst (0.150) - Miss -10.5%
12/4 Axsome Therapeutics Inc (NASDAQ: AXSM) had its price target raised by analysts at Guggenheim from $65.00 to $48.00. -8.8%
12/1 3 Top Biotech Stocks to Buy in December [The Motley Fool] -8.6%
3/24 Here's Why The Best Is Yet to Come for Axsome Therapeutics [The Motley Fool] -7.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: